For the SC cohort, mass spectrometry was used to test 214 mutations affecting 26 oncogenes and tumor suppressor genes (Panel Lungcarta© - MassARRAY iPLEX genotyping technology (Agena Bioscience, San Diego, USA), as previously described [7 (link)].
For the adenocarcinomas cohort, routine molecular analysis for EGFR, KRAS, BRAF, HER2, and PI3KCA mutations were run using the MassARRAY iPLEX genotyping technology (Agena Bioscience, San Diego, USA), enabling the detection of 159 mutations across the five genes by multiplex PCR single-base extension reactions (iPLEX chemistry). This assay was previously validated using well-characterized FFPE control samples with known mutations (Horizon diagnostics, Amplitech, Compiegne, France) or allele specific PCRs (Lightcycler, Roche). In 2014, the MassARRAY iPLEX genotyping panel involving 159 actionable targets was ISO15189 certified in our center.
For the adenocarcinomas cohort, routine molecular analysis for EGFR, KRAS, BRAF, HER2, and PI3KCA mutations were run using the MassARRAY iPLEX genotyping technology (Agena Bioscience, San Diego, USA), enabling the detection of 159 mutations across the five genes by multiplex PCR single-base extension reactions (iPLEX chemistry). This assay was previously validated using well-characterized FFPE control samples with known mutations (Horizon diagnostics, Amplitech, Compiegne, France) or allele specific PCRs (Lightcycler, Roche). In 2014, the MassARRAY iPLEX genotyping panel involving 159 actionable targets was ISO15189 certified in our center.